Alnylam Pharmaceuticals | ALNY - Selling And Administration Expenses


Alnylam Pharmaceuticals reported $347.92M in Selling and Administration Expenses for its fiscal quarter ending in June of 2026.





Selling And Administration Expenses Change Date
Acadia Pharmaceuticals USD 148.57M 12.22M Jun/2026
Agios Pharmaceuticals USD 38.46M 4.51M Mar/2026
Alnylam Pharmaceuticals USD 347.92M 65.41M Jun/2026
Amgen USD 1.72B 134M Jun/2026
Arrowhead Research USD 46.63M 4.88M Jun/2026
BioCryst Pharmaceuticals USD 63.98M 31.8M Jun/2026
BioMarin Pharmaceutical USD 395.55M 137.27M Jun/2026
Incyte USD 351.73M 23.64M Jun/2026
Ionis Pharmaceuticals USD 130.07M 20.92M Jun/2026
Moderna USD 216M 43M Jun/2026
Neurocrine Biosciences USD 383.1M 64.6M Jun/2026
Novartis USD 3.14B 296M Mar/2026
PTC Therapeutics USD 73.89M 13.31M Mar/2026
Regeneron Pharmaceuticals USD 662.1M 14.4M Jun/2026
Sangamo BioSciences USD 9.64M 1.83M Jun/2024
Sanofi EUR 2.49B 252M Mar/2026
Sarepta Therapeutics USD 107.6M 53.57M Jun/2026
Takeda JPY 286.51B 5.48B Jun/2026
Tectonic Therapeutic USD 6.43M 2.99M Mar/2026
Ultragenyx Pharmaceutical USD 88M 1000K Mar/2026
Vertex Pharmaceuticals USD 582.2M 88.5M Jun/2026
Xencor USD 77.54M 4.59M Jun/2026